Generalizability of Glucagon‐Like Peptide‐1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States

Kristina S. Boye,Matthew C. Riddle,Hertzel C. Gerstein,Reema Mody,Luis-Emilio Garcia-Perez,Chrisanthi A. Karanikas,Maureen J. Lage,Jeffrey S. Riesmeyer,Mark Lakshmanan

Generalizability of Glucagon‐Like Peptide‐1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States

2019

Kristina S. Boye
Matthew C. Riddle
Hertzel C. Gerstein
Reema Mody
Luis-Emilio Garcia-Perez
Chrisanthi A. Karanikas
Maureen J. Lage
Jeffrey S. Riesmeyer
Mark Lakshmanan

Aim To examine the generalizability of results from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes (T2D) population.

Keywords:

Glucagon-like peptide 1 receptor
Endocrinology
Dulaglutide
Type 2 diabetes
Population
Internal medicine
Medicine
Generalizability theory
Diabetes mellitus
Renal function
Myocardial infarction

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations